Objective: Kinesiotaping (KT) is a relatively new technique, which reduces the pressure on the median nerve by extending the transverse carpal ligament. The aim of this study was to evaluate the effectiveness of KT on Carpal tunnel syndrome (CTS) in a randomized, placebo-controlled manner. Methods: Patients were randomly divided into three groups: Group 1 (KT plus tendon and nerve gliding exercises), Group 2 (sham-taping plus exercises) and Group 3 (exercises alone, control group). KT was applied 3 times with 5-day intervals throughout the study, with "neural technique" for median and ulnar nerves and "area correction technique" for carpal tunnel releasing. In the placebo group kinesiotapes were applied without stretching and proper position. Hand grip strength, VAS, Boston Carpal Tunnel Syndrome Questionnaire (BCTQ), and Short Form-12 (SF-12) were measured as outcome parameters at the first visit, 3rd and 6th week.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
60
Kinesiotape, when applied with a specific method and tension, significantly reduces the pressure on the median nerve by extending the transverse carpal ligament. It regulates edema under the skin and improves lymphatic and blood circulation. It reduces muscle spasms, eases the movement of tendons and fascia, and reduces pain through neurological suppression
Tendon and nerve gliding exercise
In the sham taping group, kinesiotape was applied with two I bands without stretching and without having the proper position. This group was considered as the placebo group.
Karadeniz Technical University
Trabzon, Turkey (Türkiye)
pain level
pain level was assessed using visual analog scale.The minimum and maximum values were 0 and 10, and higher scores mean a better outcome.
Time frame: From enrollment to the end of treatment at 3 weeks
Boston Carpal Tunnel Syndrome Questionnaire (BCTQ)
The BCTQ is a disease specific questionnaire to evaluate the symptom severity and functional capacity. High scores indicate increased symtom severity and low functional capacity
Time frame: From enrollment to the end of treatment at 6 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.